255 related articles for article (PubMed ID: 38604701)
1. Chemical Strategies for the Detection and Elimination of Senescent Cells.
García-Fleitas J; García-Fernández A; Martí-Centelles V; Sancenón F; Bernardos A; Martínez-Máñez R
Acc Chem Res; 2024 May; 57(9):1238-1253. PubMed ID: 38604701
[TBL] [Abstract][Full Text] [Related]
2. Galactose-modified duocarmycin prodrugs as senolytics.
Guerrero A; Guiho R; Herranz N; Uren A; Withers DJ; Martínez-Barbera JP; Tietze LF; Gil J
Aging Cell; 2020 Apr; 19(4):e13133. PubMed ID: 32175667
[TBL] [Abstract][Full Text] [Related]
3. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells.
Escriche-Navarro B; Garrido E; Sancenón F; García-Fernández A; Martínez-Máñez R
Acta Biomater; 2024 Mar; 176():405-416. PubMed ID: 38185231
[TBL] [Abstract][Full Text] [Related]
4. Activatable senoprobes and senolytics: Novel strategies to detect and target senescent cells.
Morsli S; Doherty GJ; Muñoz-Espín D
Mech Ageing Dev; 2022 Mar; 202():111618. PubMed ID: 34990647
[TBL] [Abstract][Full Text] [Related]
5. Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs.
Chang M; Gao F; Gnawali G; Xu H; Dong Y; Meng X; Li W; Wang Z; Lopez B; Carew JS; Nawrocki ST; Lu J; Zhang QY; Wang W
J Med Chem; 2024 May; 67(9):7301-7311. PubMed ID: 38635879
[TBL] [Abstract][Full Text] [Related]
6. Cellular senescence imaging and senolysis monitoring in cancer therapy based on a β-galactosidase-activated aggregation-induced emission luminogen.
Cen P; Cui C; Huang J; Chen H; Wu F; Niu J; Zhong Y; Jin C; Zhu WH; Zhang H; Tian M
Acta Biomater; 2024 Apr; 179():340-353. PubMed ID: 38556136
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the discovery of senolytics.
Zhang L; Pitcher LE; Prahalad V; Niedernhofer LJ; Robbins PD
Mech Ageing Dev; 2021 Dec; 200():111587. PubMed ID: 34656616
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells.
Le HH; Cinaroglu SS; Manalo EC; Ors A; Gomes MM; Duan Sahbaz B; Bonic K; Origel Marmolejo CA; Quentel A; Plaut JS; Kawashima TE; Ozdemir ES; Malhotra SV; Ahiska Y; Sezerman U; Bayram Akcapinar G; Saldivar JC; Timucin E; Fischer JM
EBioMedicine; 2021 Nov; 73():103646. PubMed ID: 34689087
[TBL] [Abstract][Full Text] [Related]
9. Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies.
Khalil R; Diab-Assaf M; Lemaitre JM
Cells; 2023 Mar; 12(6):. PubMed ID: 36980256
[TBL] [Abstract][Full Text] [Related]
10. Potential Use of Senolytics for Pharmacological Targeting of Precancerous Lesions.
Saleh T; Carpenter VJ
Mol Pharmacol; 2021 Dec; 100(6):580-587. PubMed ID: 34544896
[TBL] [Abstract][Full Text] [Related]
11. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
Murakami T; Inagaki N; Kondoh H
Front Endocrinol (Lausanne); 2022; 13():869414. PubMed ID: 35432205
[TBL] [Abstract][Full Text] [Related]
12. From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs.
L'Hôte V; Mann C; Thuret JY
Open Biol; 2022 Sep; 12(9):220171. PubMed ID: 36128715
[TBL] [Abstract][Full Text] [Related]
13. A guide to senolytic intervention in neurodegenerative disease.
Lee S; Wang EY; Steinberg AB; Walton CC; Chinta SJ; Andersen JK
Mech Ageing Dev; 2021 Dec; 200():111585. PubMed ID: 34627838
[TBL] [Abstract][Full Text] [Related]
14. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
[TBL] [Abstract][Full Text] [Related]
15. Senolysis Enabled by Senescent Cell-Sensitive Bioorthogonal Tetrazine Ligation.
Chang M; Dong Y; Xu H; Cruickshank-Taylor AB; Kozora JS; Behpour B; Wang W
Angew Chem Int Ed Engl; 2024 Feb; 63(9):e202315425. PubMed ID: 38233359
[TBL] [Abstract][Full Text] [Related]
16. Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker.
Poblocka M; Bassey AL; Smith VM; Falcicchio M; Manso AS; Althubiti M; Sheng X; Kyle A; Barber R; Frigerio M; Macip S
Sci Rep; 2021 Oct; 11(1):20358. PubMed ID: 34645909
[TBL] [Abstract][Full Text] [Related]
17. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
Hickson LJ; Langhi Prata LGP; Bobart SA; Evans TK; Giorgadze N; Hashmi SK; Herrmann SM; Jensen MD; Jia Q; Jordan KL; Kellogg TA; Khosla S; Koerber DM; Lagnado AB; Lawson DK; LeBrasseur NK; Lerman LO; McDonald KM; McKenzie TJ; Passos JF; Pignolo RJ; Pirtskhalava T; Saadiq IM; Schaefer KK; Textor SC; Victorelli SG; Volkman TL; Xue A; Wentworth MA; Wissler Gerdes EO; Zhu Y; Tchkonia T; Kirkland JL
EBioMedicine; 2019 Sep; 47():446-456. PubMed ID: 31542391
[TBL] [Abstract][Full Text] [Related]
18. Quantitative identification of senescent cells in aging and disease.
Biran A; Zada L; Abou Karam P; Vadai E; Roitman L; Ovadya Y; Porat Z; Krizhanovsky V
Aging Cell; 2017 Aug; 16(4):661-671. PubMed ID: 28455874
[TBL] [Abstract][Full Text] [Related]
19. Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics.
Gao Y; Wu T; Tang X; Wen J; Zhang Y; Zhang J; Wang S
Geroscience; 2023 Jun; 45(3):1775-1790. PubMed ID: 36648735
[TBL] [Abstract][Full Text] [Related]
20. Promises and challenges of senolytics in skin regeneration, pathology and ageing.
Pils V; Ring N; Valdivieso K; Lämmermann I; Gruber F; Schosserer M; Grillari J; Ogrodnik M
Mech Ageing Dev; 2021 Dec; 200():111588. PubMed ID: 34678388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
